latest news releases from the newsroom
InterAge Closes Contract for Web-Based Marketing Project
CESAREA, Israel, March 29, 2006 (PRIMEZONE) -- InterAge Ltd. (Pink Sheets:ITRJ), a leading provider of integrated web marketing solutions, announced today that it signed a contract to supply all the web-based marketing needs for Play65.com (www.play65.com/EN/index.html), a Backgammon gaming web site.
ReelTime Attending MIPTV 2006 in Cannes, France
SEATTLE, March 29, 2006 (PRIMEZONE) -- Reeltime Rentals, Inc., (Pink Sheets:RLTR), announces today that the Company's Vice President of Acquisitions and Business Development, Beverly Zaslow, will be attending the MIPTV 2006 conference in Cannes, France on April 3 -- 7. Ms. Zaslow has regularly attended the bi-annual conference in Cannes over the past twenty years, often speaking and participating in panel discussions. MIPTV featuring MILIA is the world's largest interactive forum for content creation, production and distribution across all traditional, digital and Telcos TV platforms. This year's MIPTV conference will focus on the impact of the digital revolution on the way media is being delivered to consumers.
Gardant Pharmaceuticals, Inc.
Bioaccelerate Announces Changes in Management
NEW YORK, March 29, 2006 (PRIMEZONE) -- Bioaccelerate Holdings, Inc, (OTCBB:BACL), which has previously announced it is changing its name to Gardant Pharmaceuticals, Inc., today announced that in connection with the Company's recently announced change in strategy, including the plan to spin off a number of the Company's subsidiaries to the Company's shareholders, management roles in the Company's subsidiaries have been realigned. It is anticipated that Dr. Nigel Rulewski will become CEO of Cynat Oncology, Inc., Christopher O'Toole will become CEO of Amilar Pharmaceuticals, Inc., Mark Davison will become CEO of Genaderm Inc., and Bruce Murdoch will become CEO of Anvira, Inc. Bioaccelerate's new strategy means that the company will no longer require a significant management infrastructure but will instead be able to focus resources on its principal operating companies where greater value will be realized. The Company announced that in view of this change in direction, Dr. Frank Armstrong's relationship with the Company and its subsidiaries has been terminated by mutual agreement in order to allow Dr. Armstrong to pursue other opportunities.